This article is more than 5 years old. Information may no longer be current.

Alberta research fund aims to advance diabetes discoveries

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A new collaboration between the Alberta Diabetes Institute at the University of Alberta and Janssen Inc. in Canada will support research in type 1 and type 2 diabetes, specifically focused on novel research with potential for commercialization.

The 3-year, $600,000, competitive Johnson & Johnson Diabetes Research Fund — backed by Janssen along with the Government of Alberta and the Alberta Diabetes Foundation — aims to advance early stage technologies related to diabetes.

“This collaboration of funding partners exemplifies the good will of the private, public and philanthropic organizations to work together to best serve patients,” Douglas Miller, MD, CM, FRCPC, dean of the Faculty of Medicine & Dentistry at the University of Alberta, said in a press release.

The Alberta Diabetes Institute and technical experts from Johnson & Johnson Innovation Center in California will identify high-potential opportunities from medical researchers across the Canadian province and award up to $50,000 for a year.

All research around diabetes is eligible for the funding. The collaboration expects to receive proposals that lead to development of drugs, devices and cell therapies, as well as diagnosis, treatment and management of type 1 and type 2 diabetes.